Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Nintedanib | Lung Cancer

Nintedanib for Treatment of Advanced Lung Cancer

Posted on November 25, 2019
Post Views: 499

NintedanibNovember is recognized as Lung Cancer Awareness Month all over the world. New and advanced researches continue to work in the arena of lung cancer treatment. The University of Barcelona and Hospital Clinic de Barcelona has collaborated with Boehringer Ingelheim Inc. with the purpose of improving efficiency of Nintedanib, an anti-angieogenic and anti-fibrotic drug for lung cancer treatment. This collaboration enabled researchers to identify molecular mechanisms underlying lack of efficiency of this drug in non-small cell lung cancer. The results were published in Journal Cancer Research and could have implications in design of new therapeutic strategies to expand clinical benefits of the drug.

Nintedanib drug is developed by Boehringer Ingelheim and it showed therapeutic benefits in patients suffering from advanced lung adenocarcinoma. Its action mechanism is based on inhibition of receptors involved in formation  of new vessels and fibrosis.

Skeletal Model of Nintedanib

Jordi Alcaraz, researcher at CIBERES says, “The results describe for the first time that tumor fibrosis is higher in adecarcinoma than in squamous cell carcinoma, which causes patients with adenocarcinoma to respond better to treatment with nintedanib. Furthermore, we identify the underlying mechanism: the pro-fibrotic transcription factor SMAD3 in fibroblasts- the main cells that drive fibrosis- is more epigenetically repressed in squamous cell carcinoma than in adenocarcinoma, and this makes patients with squamous cell carcinoma to have less fibrosis and to be resistant to nintedanib.”

The results of the study could have further implications in design of therapeutical strategies to treat lung cancer with different drug combinations. The results published in Journal Cancer Research, help to expand the clinical benefits of the drug to large spectra of lung cancer patients. This study also identified the role of smoking in the lack of efficiency of drugs against this deadly disease.

The information shared in this blog is for educational purposes only.

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,303)
  • Lung Cancer: Symptoms and Treatment (5,625)
  • What is Non-Small-Cell Lung Cancer? (5,531)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025
  • Lung Cancer Screening Is Beneficial For Non-Smokers As Well April 28, 2025
  • Understanding The Stage 0 Lung Cancer April 21, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
%d